← Back to All US Stocks

Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) Fundamental Analysis & AI Grade 2026

RAJAF OTC Medicinal Chemicals & Botanical Products CIK: 0001885680
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

RAJAF Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

RAJAF vs Materials Sector: How Cordyceps Sunshine Biotech Holdings Co., Ltd. Compares

How Cordyceps Sunshine Biotech Holdings Co., Ltd. compares to Materials sector averages

Net Margin
RAJAF 0.0%
vs
Sector Avg 10.0%
RAJAF Sector
ROE
RAJAF 0.0%
vs
Sector Avg 14.0%
RAJAF Sector
Current Ratio
RAJAF 0.0x
vs
Sector Avg 1.6x
RAJAF Sector
Debt/Equity
RAJAF 0.0x
vs
Sector Avg 0.6x
RAJAF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Cordyceps Sunshine Biotech Holdings Co., Ltd. Stock Overvalued? RAJAF Valuation Analysis 2026

Based on fundamental analysis, Cordyceps Sunshine Biotech Holdings Co., Ltd. has mixed fundamental signals relative to the Materials sector in 2026.

Return on Equity
N/A
Sector avg: 14%
Net Profit Margin
N/A
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Cordyceps Sunshine Biotech Holdings Co., Ltd. Balance Sheet: RAJAF Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

RAJAF Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

RAJAF SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Cordyceps Sunshine Biotech Holdings Co., Ltd. (CIK: 0001885680)

Frequently Asked Questions about RAJAF

What is the AI rating for RAJAF?

Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are RAJAF's key strengths?

Claude: Analysis in progress.

What are the risks of investing in RAJAF?

Claude: Analysis in progress.

What is RAJAF's revenue and growth?

Cordyceps Sunshine Biotech Holdings Co., Ltd. reported revenue of N/A.

Does RAJAF pay dividends?

Cordyceps Sunshine Biotech Holdings Co., Ltd. does not currently pay dividends.

Where can I find RAJAF SEC filings?

Official SEC filings for Cordyceps Sunshine Biotech Holdings Co., Ltd. (CIK: 0001885680) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is RAJAF's EPS?

Cordyceps Sunshine Biotech Holdings Co., Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is RAJAF's fundamental grade?

Based on our AI fundamental analysis in May 2026, Cordyceps Sunshine Biotech Holdings Co., Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is RAJAF stock overvalued or undervalued?

Valuation metrics for RAJAF: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

What is RAJAF's AI grade for 2026?

Our dual AI analysis gives Cordyceps Sunshine Biotech Holdings Co., Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is RAJAF's free cash flow?

Cordyceps Sunshine Biotech Holdings Co., Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does RAJAF compare to other Materials stocks?

Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI